FrancophonIA/ELRC3.0 huggingface dataset:
English: When the receptors are activated, the break down of fats is accelerated, and this helps clear the blood of cholesterol and triglycerides.
Estonian: Kui retseptor on aktiveeritud, siis rasvade lagunemine kiireneb, mis aitab eemaldada verest kolesterooli ja triglütseriide.
English: Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of fibrates continue to outweigh their risks within these restrictions.
Estonian: Tuginedes olemasolevatele andmetele ja komiteesisesele teaduslikule arutelule, leidis inimravimite komitee, et nimetatud piiranguid arvestades on fibraatide kasulikkus endiselt suurem kui kaasnevad riskid.
English: • Doctors are reminded that fibrates should not be used as first-line treatment in patients with high lipid levels, except in specific groups: patients with severe hypertriglyceridaemia; patients for whom statins are contra-indicated or who cannot tolerate them.
Estonian: • Arstidele tuletatakse meelde, et fibraate ei tohi kasutada esmavaliku ravimitena vere suure lipiidisisaldusega patsientide puhul, v.a teatud patsiendirühmade korral: raske hüpertriglütserideemiaga patsiendid; patsiendid, kellele on statiinid vastunäidustatud või kes neid ei talu.
English: The aim of the review was to establish how fibrates should now be used, taking into account their safety, their effectiveness in lowering lipid levels and the availability of other lipid-lowering medicines that were not around when fibrates were first used.
Estonian: Läbivaatamise eesmärk oli leida, kuidas tuleb fibraate praegu kasutada, arvestades nende ohutust, efektiivsust lipiidisisalduse vähendamisel ja muude selliste lipiidisisaldust vähendavate ravimite kättesaadavust, mis fibraatide kasutuselevõtu ajal veel puudusid.
English: • Gemfibrozil.
Estonian: • Gemfibrosiil.
English: • Patients who are currently taking fibrates to lower their blood lipid levels should continue to do so.
Estonian: • Patsiendid, kes praegu kasutavad vere lipiidisisalduse vähendamiseks fibraate, peavad ravi jätkama.
English: The conclusions of the PhVWP were transmitted to the companies that market fibrates, so that they could implement the changes recommended by the working party.
Estonian: Inimravimite komitee ravimiohutuse järelevalve töörühma järeldused edastati fibraate turustavatele ettevõtetele, et nad teeksid töörühma soovitatud muudatused.
English: Fibrates should be used only when statins are contraindicated or not tolerated.
Estonian: Fibraate tohib kasutada üksnes siis, kui statiinid on vastunäidustatud või kui patsient neid ei talu.
English: • However, patients taking a fibrate-containing medicine should arrange to see their doctor to check that the medicine is the most appropriate option to lower their blood lipid levels.
Estonian: • Fibraati sisaldavaid ravimeid kasutavad patsiendid peavad siiski paluma arstil kontrollida, kas kasutatav ravim on nende korral vere lipiidisisalduse vähendamiseks sobivaim valik.
English: However, fibrates can be used in patients who cannot take statins (another type of medicine used to lower blood lipid levels).
Estonian: Küll aga tohib fibraate kasutada patsientidel, kes ei saa kasutada statiine (samuti vere lipiidisisalduse vähendamise ravimid).
English: The CHMP looked at the information gathered by PhVWP during its review, as well as the responses provided by the companies to specific questions.
Estonian: Inimravimite komitee vaatas läbi teabe, mille oli kogunud ravimiohutuse järelevalve töörühm andmete taasläbivaatamise käigus, ja vastused, mida ettevõtted olid andnud konkreetsetele küsimustele.
English: Fibrates are a class of medicines that can be used to lower the level of lipids, such as cholesterol and triglycerides, in the blood.
Estonian: Fibraadid on ravimirühm, mida saab kasutada vere lipiidi-, näiteks kolesterooli- ja triglütseriidisisalduse vähendamiseks.
English: As a result, the Committee also allowed the use of fenofibrate together with a statin in some circumstances for patients at risk when using a statin on its own was not enough to completely control blood lipid levels.
Estonian: Inimravimite komitee lubas seetõttu fenofibraadi kasutamist koos statiiniga riskipatsientidel olukorras, kus statiinist üksi ei piisa, et täielikult reguleerida vere lipiidisisaldust.
English: In 2005, the CHMP's PharmacoVigilance Working Party (PhVWP) noted that there was limited evidence of the long-term benefit of fibrates in reducing cardiovascular risk, compared with the stronger evidence for statins (another type of medicines used for lowering blood cholesterol).
Estonian: 2005. aastal märkis inimravimite komitee ravimiohutuse järelevalve töörühm, et fibraatide pikaajalise kasulikkuse kohta kardivaskulaarriski vähendamisel on vähem andmeid kui satiinide kohta (samuti vere lipiidisisalduse vähendamise ravimid).
English: This means that newlydiagnosed patients with blood lipid disorders should not be treated using these medicines in the first instance, unless they have very high levels of triglycerides (a type of fat).
Estonian: See tähendab, et verelipiidide häire esmase diagnoosiga patsiendid ei tohi neid ravimeid kasutada esmavaliku ravimitena, v.a kui neil on triglütseriidide (teatud rasvad) sisaldus väga suur.
English: The Committee also looked at the latest data from clinical studies including a trial looking at the effect of using fenofibrate as an ‘add-on' to statins.
Estonian: Komitee vaatas läbi ka uusimad andmed, mis on saadud kliinilistest uuringutest, sealhulgas uuringust, kus kontrolliti fenofibraadi toimet kasutamisel statiinide lisaravimina.
English: The Committee endorsed the conclusions of the PhVWP that fibrates are still a safe option for lowering lipid levels, but that their use as first-line treatment is not justified.
Estonian: Komitee kiitis heaks ravimiohutuse järelevalve töörühma järelduse, et fibraadid on endiselt ohutu võimalus lipiidisisalduse vähendamiseks, kuid nende kasutamine esmavaliku ravimitena ei ole põhjendatud.
English: • They should review the treatment of patients who are receiving fibrates to help control their lipid levels to ensure that the patient is receiving the most appropriate treatment.
Estonian: • Arstidel soovitatakse lipiidisisalduse reguleerimiseks fibraate kasutavate patsientide ravi üle vaadata, et veenduda, et patsient saab sobivaimat ravi.
English: However, the Committee noted that fibrates are more effective than statins in lowering triglyceride levels and therefore their use as a first-line treatment in patients with severe hypertriglyceridaemia (very high blood levels of triglycerides) is still appropriate.
Estonian: Samas märkis komitee, et triglütseriidisisalduse vähendamisel on fibraadid statiinidest efektiivsemad, mille tõttu võib endiselt soovitada nende kasutamist esmavaliku ravimitena patsientidel, kellel on raske hüpertriglütserideemia (vere väga suur triglütseriidisisaldus).
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of fibrates continue to outweigh their risks but that they should not be used as ‘first line' in the treatment of blood lipids (fats) disorders, such as high cholesterol, except in rare cases.
Estonian: EMA inimravimite komitee järeldas, et fibraatide kasulikkus on endiselt suurem kui nendega kaasnevad riskid, kuid fibraate ei tohi kasutada esmavaliku ravimitena veres sisalduvate lipiididega (rasvad) seotud häirete (nt suur kolesteroolisisaldus) ravimiseks, välja arvatud harvadel juhtudel.
English: • Ciprofibrate.
Estonian: • Tsiprofibraat.
English: • Fenofibrate.
Estonian: • Fenofibraat.
English: Looking at the data, the PhVWP came to the conclusion that there were no new safety issues with fibrates and that fibrate-containing medicines still had a role to play in improving lipid levels, but that they should not be used as first-line treatment.
Estonian: Andmete põhjal järeldas ravimiohutuse järelevalve töörühm, et fibraatide korral ei ole esinenud uusi ohutusprobleeme ja fibraate sisaldavad ravimid on lipiidisisalduse vähendamisel endiselt vajalikud, kuid neid ei tohi kasutada esmavaliku ravimitena.
English: This means that they activate a type of receptor called the ‘peroxisome proliferator activated receptor'.
Estonian: Fibraadid on PPAR-agonistid ehk ained, mis aktiveerivad peroksisoomi proliferaatori aktiveeritava retseptori (PPAR).
English: The Committee also noted that there were new data for fenofibrate that supported a change to the PhVWP recommendations, based on the results of the add-on study.
Estonian: Samuti märkis inimravimite komitee, et fenofibraadi kohta on lisauuringu tulemusel olemas uusi andmeid, mille alusel saab muuta ravimiohutuse järelevalve töörühma soovitusi.
English: Austria, Belgium, Cyprus, Finland, France, Germany; Greece, Hungary, Italy, Luxembourg,
Estonian: Austrias, Belgias, Küprosel, Soomes, Prantsusmaal, Saksamaal, Kreekas, Ungaris, Itaalias,
English: It is marketed mainly under the trade names Bezalip, Cedur, Eulitop and Befizal, as well as generic medicines.
Estonian: Bezalip, Cedur, Eulitop ja Befizal all, samuti geneeriliste ravimitena.
English: It is sold in Austria, Cyprus, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, the Netherlands, Portugal, Slovenia, Slovakia, Spain, Sweden and the United Kingdom.
Estonian: Ravimil on müügiluba Austrias, Küprosel, Taanis, Soomes, Prantsusmaal, Saksamaal, Kreekas, Ungaris, Islandil, Iirimaal, Itaalias, Madalmaades, Portugalis, Sloveenias, Slovakkias, Hispaanias, Rootsis ja Ühendkuningriigis.
English: Malta, the Netherlands, Portugal, Romania, Spain, Sweden and the United Kingdom;
Estonian: Luksemburgis, Maltal, Madalmaades, Portugalis, Rumeenias, Hispaanias, Rootsis ja
English: This medicine has been available since 1977.
Estonian: Ravimit turustatakse alates 1977. aastast, peamiselt kaubanduslike nimetuste
English: It is marketed mainly under the trade name Lopid, as well as generic medicines.
Estonian: Ravimit turustatakse alates 1981. aastast, peamiselt kaubandusliku nimetuse Lopid all, samuti geneeriliste ravimitena.
English: It is marketed mainly under the trade name Lipanthyl, as well as generic medicines.
Estonian: Ravimit turustatakse alates 1975. aastast, peamiselt kaubandusliku nimetuse Lipanthyl all, samuti geneeriliste ravimitena.
English: Cyprus, the Czech Republic, Estonia, France, Greece, Hungary, Latvia, Lithuania, Luxembourg, the Netherlands, Poland, Portugal, Romania, Slovakia and the United Kingdom;
Estonian: Ravimil on müügiluba Belgias, Bulgaarias, Küprosel, Tšehhi Vabariigis, Eestis, Prantsusmaal, Kreekas, Ungaris, Lätis, Leedus, Luksemburgis, Madalmaades, Poolas, Portugalis, Rumeenias, Slovakkias ja Ühendkuningriigis.
English: Blood lipid disorders are a risk factor of heart disease (such as heart attack and stroke) and fibrates are used to improve lipid levels in patients in whom dietary restrictions and exercise have not been enough.
Estonian: Verelipiidide häired on südamehaiguste (näiteks infarkti ja insuldi) riskitegur.
English: It is sold in
Estonian: Ravimil on müügiluba
English: It is marketed mainly under the trade name Lipanor or Modalim, as well as generic medicines.
Estonian: Ravimit turustatakse alates 1995. aastast, peamiselt kaubanduslike nimetuste Lipanor ja Modalim all, samuti geneeriliste ravimitena.
English: Date of first authorisation: 6 January 2011 Date of latest renewal: 5 October 2015
Estonian: Müügiloa esmase väljastamise kuupäev: 06. jaanuar 2011 Müügiloa viimase uuendamise kuupäev: 05. oktoober 2015
English: Vials 4 years.
Estonian: Viaalid 4 aastat.
English: Each pack contains one vial.
Estonian: Iga pakend sisaldab üht viaali.
English: As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much.
Estonian: Kuna seda ravimit manustab teile arst või meditsiiniõde, on see ebatõenäoline, et te saate liiga palju ravimit.
English: The experience in children and adolescents is limited and treatment is therefore not recommended.
Estonian: Kogemus laste ja noorukite ravis on piiratud ja seetõttu ei ole soovitatav.
English: Your dose of Potactasol may need to be adjusted.
Estonian: Teie Potactasol'i annust võib olla tarvis kohandada.
English: If you are or think you might be pregnant, tell your doctor immediately.
Estonian: Kui te olete rase või arvate end olevat rase, öelge seda kohe oma arstile.
English: Other medicines and Potactasol
Estonian: Muud ravimid ja Potactasol
English: Always wash hands after removing gloves.
Estonian: Pärast kinnaste äravõtmist pesta alati käsi.
English: Potactasol should not be used in pregnant women, unless clearly necessary.
Estonian: Potactasol'i ei tohi kasutada rasedatel naistel, välja arvatud juhul, kui see on absoluutselt vajalik.
English: Potactasol can make you feel tired or weak.
Estonian: Potactasol võib põhjustada väsimust ja nõrkust.
English: Potactasol is available in cartons containing 1 vial.
Estonian: Potactasol on saadaval karpides, mis sisaldavad 1 viaali.
English: In some cases you may need a blood transfusion.
Estonian: Mõnel juhtul võite te vajada vereülekannet.
English: This concentrate (1 mg/ml) must be diluted prior to administration.
Estonian: Seda kontsentraati (1 mg/ml) tuleb enne manustamist veel lahjendada.
English: Tell your doctor or nurse if you have any concerns about the amount of medicine that you receive.
Estonian: Öelge oma arstile või meditsiiniõele, kui te tunnete muret teile manustatava ravimi koguse pärast.
English: Accurate assessment of performance status at the time therapy is given is important, to ensure that patients have not deteriorated to PS 3.
Estonian: Tähtis on patsientide üldseisundi täpne hindamine ravi ajal veendumaks, et see ei ole halvenenud PS 3 astmeni.
English: The doctor will evaluate your general health during the treatment and you should tell him/her in case you have fever, infection or are in some ways feeling unwell.
Estonian: Arst hindab ravi ajal teie üldist tervislikku seisundit ja te peate talle ütlema, kui teil on palavik, põletik või te tunnete end muul moel halvasti.
English: - Itching (pruritus).
Estonian: - Kihelus (pruritus).
English: extravasation3
Estonian: ekstravasatsioon3
English: Topotecan also had a high volume of distribution, about 132 l, (SD 57), and a relatively short half-life of 2-3 hours.
Estonian: Topotekaanil oli ka suur jaotusruumala, ligikaudu 132 l, (SD 57) ja suhteliselt lühike poolväärtusaeg (2...3 tundi).
English: Response rate (%)
Estonian: Ravivastuse määr (%)
English: For more information about cisplatin, please refer to the corresponding package leaflet.
Estonian: Rohkema informatsiooni saamiseks tsisplatiini kohta, palun lugege vastavat pakendi infolehte.
English: What you need to know before you use Potactasol Do not use Potactasol
Estonian: Mida on vaja teada enne Potactasol'i kasutamist Ärge kasutage Potactasol'i
English: If you are given too much Potactasol
Estonian: Kui teile manustatakse liiga palju Potactasol'i
English: In addition, 5 % of all patients treated (1 % of courses) developed sepsis (see section 4.4).
Estonian: Peale selle arenes 5%l kõigist ravitud patsientidest (1% ravikuuride lõikes) sepsis (vt lõik 4.4).
English: Do not use this medicine after the expiry date which is stated on the vial and carton after EXP.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud viaalil ja karbil paräst „EXP“.
English: − Pregnant staff should be excluded from working with this medicinal product.
Estonian: - Rasedad töötajad peavad hoiduma selle ravimiga töötamisest.
English: The median time to response in clinical studies was 7.6-11.6 weeks.
Estonian: Kliinilistes uuringutes oli ravivastuse saabumise aja mediaan 7,6...11,6 nädalat.
English: Median time to progression was similar in the two groups (13.3 weeks and 12.3 weeks, respectively).
Estonian: Mediaalne aeg haiguse progresseerumiseni oli kahes grupis sarnane (vastavalt 13,3 ja 12,3 nädalat).
English: The preparation should be performed in a designated area under aseptic conditions.
Estonian: Ettevalmistused tuleb läbi viia aseptilistes tingimustes ja ainult selleks ettenähtud alal.
English: A doctor or nurse will give you the reconstituted and diluted Potactasol solution as an infusion (drip), usually into your arm, over about 30 minutes.
Estonian: Arst või õde manustab teile lahustatud ja lahjendatud Potactasol'i lahust tavaliselt infusioonina (tilgana) käe veeni, umbes 30 minuti jooksul.
English: This condition can be fatal.
Estonian: See seisund võib lõppeda surmaga.
English: What Potactasol is and what it is used for What you need to know before you use Potactasol How to use Potactasol
Estonian: Mis ravim on Potactasol ja milleks seda kasutatakse Mida on vaja teada enne Potactasol'i kasutamist Kuidas Potactasol'i kasutada Võimalikud kõrvaltoimed
English: Among all patients treated in clinical studies (including both those with severe neutropenia and those who did not develop severe neutropenia), 11 % (4 % of courses) developed fever and 26 % (9 % of courses) developed infection.
Estonian: Kliiniliste uuringute käigus ravitud kõigist patsientidest (sh need, kellel arenes raske neutropeenia, kui ka need, kellel seda ei arenenud) tekkis 11%-l (4% ravikuuride lõikes) palavik ja 26%-l (9% ravikuuride lõikes) infektsioon.
English: Your dose of Potactasol will depend on: - the disease being treated, - your body surface area (m2), - the results of blood tests carried out before and during treatment, - how well you tolerate treatment.
Estonian: Teie Potactasol'i annus sõltub: - ravitavast haigusest, - teie kehapindalast (m2), - enne ravi ja ravi ajal tehtud vereanalüüside vastustest, - kui hästi te ravi talute.
English: - The active substance is topotecan.
Estonian: - Toimeaine on topotekaan.
English: - if you are allergic to topotecan or any of the other ingredients of this medicine (listed in section 6); - if you are breast-feeding.
Estonian: - kui olete topotekaani või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline; - kui te toidate rinnaga; - kui teie vererakkude arv on liiga madal.
English: Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Estonian: (≥ 1/100 kuni < 1/10); aeg-ajalt (≥ 1/1000 kuni < 1/100); harv (≥ 1/10 000 kuni < 1/1000); väga harv (< 1/10 000) ja teadmata (ei saa hinnata olemasolevate andmete alusel).
English: If you are being treated for cervical cancer, you may get side effects from the other medicine (cisplatin) that you will be given along with Potactasol.
Estonian: Kui te saate emakakaelavähi vastast ravi, võivad teil tekkida kõrvaltoimed, mis on tingitud teisest ravimist (tsisplatiin), mida te saate koos Potactasol'iga.
English: Other side effects with Potactasol include: Very common side effects (may affect more than 1 in 10 people)
Estonian: Teised Potactasol'i kõrvaltoimed on: Väga sagedased kõrvaltoimed (võivad ilmneda rohkem kui 1 inimesel 10`st):
English: Topotecan should only be administered under the supervision of a physician experienced in the use of chemotherapy (see section 6.6).
Estonian: Topotekaani tohib manustada ainult kemoteraapias kogenud arsti järelevalve all (vt lõik 6.6).
English: What Potactasol is and what it is used for
Estonian: Mis ravim on Potactasol ja milleks seda kasutatakse
English: In patients refractory to, or relapsing within 3 months after cisplatin therapy (n = 186), the response rate was 10 %.
Estonian: Patsientidel, kes allusid raskesti ravile või kellel esines retsidiiv 3 kuu jooksul pärast tsisplatiinravi (n = 186), oli ravivastuse määr 10%.
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
Estonian: Kui lahust ei kasutata kohe, on kõlblikkusaeg ja säilitamistingimused kasutaja vastutusel ega tohiks tavaliselt ületada 24 tundi temperatuuril 2°C kuni 8°C, välja arvatud juhul, kui lahjendamine/manustamiskõlblikuks muutmine on toimunud kontrollitud ja valideeritud aseptilistes tingimustes..
English: - Allergic (hypersensitivity) reactions (including rash).
Estonian: - Allergilised (ülitundlikkus) reaktsioonid (s.h lööve).
English: Frequently reported non-haematological effects were gastrointestinal such as nausea (52 %), vomiting (32 %), diarrhoea (18 %), constipation (9 %) and mucositis (14 %).
Estonian: Sagedamini registreeritud mittehematoloogilisteks kõrvaltoimeteks olid seedetrakti häired, nagu iiveldus (52%), oksendamine (32%), kõhulahtisus (18%), kõhukinnisus ( 9%) ja mukosiit (14%).
English: In clinical studies, topotecan was discontinued if the dose had been reduced to 1.0 mg/m2/day and a further dose reduction was required to manage adverse effects.
Estonian: Kliinilistes uuringutes katkestati topotekaani manustamine, kui annust oli vähendatud kuni 1,0 mg/m2 ööpäevas ja kõrvaltoimete ohjeldamiseks oleks olnud vajalik annuse edasine vähendamine.
English: Overall, the N-desmethyl metabolite contributed a mean of less than 7 % (range 4-9 %) of the total topotecan-related material accounted for in the urine and faeces.
Estonian: Üldiselt moodustas N-desmetüülmetaboliit keskmiselt alla 7% (vahemik 4...9%) kogu topotekaaniga seotud materjalist uriinis ja roojas.
English: This should be taken into account, when prescribing topotecan, e.g. if patients at increased risk of tumour bleeds are considered for therapy.
Estonian: Seda tuleb arvesse võtta, kui topotekaani määratakse näiteks juhul, kui ravi alustamist kaalutakse patsientidel, kellel on suurenenud risk kasvaja verejooksu tekkeks.
English: As would be expected, patients with poor performance status (PS > 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).
Estonian: Halvas üldseisundis (performance status, PS > 1) patsientide ravivastus on oodatult väiksem ning komplikatsioonide nagu palavik, infektsioon ja sepsis - oht on suurenenud (vt lõik 4.8).
English: Potactasol is for intravenous infusion after reconstitution and dilution.
Estonian: Potactasol on intravenoosseks infusiooniks pärast lahustamist ja lahjendamist.
English: Cytotoxic, special handling instructions (see package leaflet).
Estonian: Tsütotoksiline, erikäitlemisjuhis (vt pakendi infolehte).
English: The mean metabolite:parent AUC ratio was < 10 % for both total topotecan and topotecan lactone.
Estonian: Metaboliidi:topotekaani AUC keskmine suhe oli < 10% nii kogu topotekaani kui topotekaanlaktooni puhul.
English: In a population of patients with refractory SCLC (those not responding to first-line therapy), the response rate to topotecan was 4.0 %.
Estonian: Refraktaarse SCLC-ga patsientidel (kes ei reageerinud esimese rea ravile) oli topotekaanravile reageerimise sagedus 4,0%.
English: You must tell your doctor immediately if you experience any of the following serious side effects.
Estonian: Öelge kohe oma arstile, kui teil tekib mistahes järgmistest kõrvaltoimetest.
English: Then seek medical evaluation by a physician.
Estonian: Seejärel tuleb pöörduda kontrolliks arsti poole.
English: Potactasol contains the active substance topotecan which helps to kill tumour cells.
Estonian: Potactasol sisaldab toimeainet topotekaani, mis aitab hävitada kasvajarakke.
English: For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.
Estonian: Säilitamistingimused pärast ravimpreparaadi manustamiskõlblikuks muutmist ja lahjendamist vt lõik 6.3.
English: - Swelling caused by fluid build-up (angioedema) e.g. around the eyes and lips as well as hands,
Estonian: - Vedeliku kuhjumisest põhjustatud tursed (angioödeem) - nt silmade ja huulte ümbruses, aga ka kätel, jalgadel ja kõris.